{"filings":[{"id":2198761,"accession_number":"0000950103-26-012223","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2026-08-12T11:01:08+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb names Thomas J. Appio Chairman, appoints Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas J. Appio succeeded Brent Saunders as Chairman of the Board effective Aug 10, 2026; Saunders remains a director.","Dr. Laurence Paul appointed Lead Independent Director, also joining Nominating and Science & Technology committees.","Committee chairs set Aug 10: Paulson (Nominating), Alfonso (Science & Tech), Trebbi (Talent & Comp); Chersi added to Audit and Talent & Comp.","All board and committee changes effective Aug 10, 2026, following earlier resignations and new director appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088162,"accession_number":"0000950103-26-011979","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-08-06T11:10:22+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb appoints four new directors, reaffirms 2026 guidance after Q2 revenue of $1.394B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 revenue $1.394B, up 9% reported and 8% constant currency vs Q2 2025; broad-based double-digit growth in Surgical and Pharma.","Cash flow from operations rose to $153M in Q2 from $32M in Q1; adjusted cash flow from operations $161M.","Full-year 2026 guidance reaffirmed: revenue $5.44B–$5.54B, Adj EBITDA (ex-IPR&D) $1.025B–$1.075B.","Board adds Thomas Appio (CEO of Bausch Health), Robert Chersi, Laurence Paul, and Barbara Trebbi; four prior directors resigned.","Resignations not due to disagreement; departing directors receive prorated cash and full RSU vesting; Thomas Ross gets $400K consulting fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1922558,"accession_number":"0001860742-26-000086","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-07-29T11:02:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q2 revenue $1.394B (+9% YoY); raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.394B, up 9% reported and 8% constant currency YoY; GAAP net loss $14M vs $62M loss.","Adjusted EBITDA $241M (+$50M YoY); Adjusted EBITDA ex-IPR&D $246M.","Surgical revenue +19% (premium IOLs up 175%); Pharmaceuticals +15% (MIEBO/XIIDRA +27% H1).","FY2026 revenue guidance raised to $5.44B-$5.54B; Adj. EBITDA ex-IPR&D raised to $1.025B-$1.075B.","Cash flow from operations $153M, up from $35M; GAAP EPS ($0.04), adjusted EPS $0.15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555396,"accession_number":"0001193125-26-232712","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-05-20T20:32:56+00:00","items":["5.07"],"status":"ready","headline":"BLCO shareholders re-elect all 10 directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected, each with ~331.5M votes for, ~4.2M against, ~11.5M broker non-votes.","Advisory vote on executive compensation passed: 328.1M for, 0.8M against, 6.9M abstain.","PricewaterhouseCoopers LLP ratified as independent auditor: 343.3M for, 4.0M withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96351,"accession_number":"0001860742-26-000060","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 2026 revenue $1.244B (+9% YoY), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.244B, up 9% reported and 6% constant currency YoY; GAAP net loss narrowed to $71M from $212M.","Adjusted EBITDA (non-GAAP) $189M vs $98M prior year; adjusted EPS $0.05 vs -$0.15.","Raising 2026 revenue guidance to $5.42B-$5.52B (was $5.375B-$5.475B) and Adj. EBITDA ex-IPR&D to $1.01B-$1.06B.","Pharmaceuticals segment grew 12% constant currency; MIEBO (+33%) and XIIDRA (+30%) led growth.","Vision Care +5% constant currency; Surgical +1% constant currency; double-digit growth in daily SiHy lenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":1244000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110175,"accession_number":"0001860742-26-000006","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4 rev $1.405B (+10%), net loss $58M; guides FY2026 rev $5.375B-$5.475B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.405B (+10% reported, +7% constant currency); FY revenue $5.101B (+6% reported, +5% constant currency).","Q4 GAAP net loss $58M (vs $3M loss in Q4 2024); FY net loss $360M (vs $317M).","Q4 adjusted EBITDA $326M (+$67M YoY); adjusted EPS $0.32 (vs $0.25). FY adjusted EBITDA $858M; adjusted EPS $0.43.","Segment: Vision Care $778M (+8%), Surgical $249M (+8%), Pharma $378M (+16%); MIEBO sales $112M in Q4.","FY2026 guidance: revenue $5.375B-$5.475B (5-7% constant currency growth); adjusted EBITDA ex-IPR&D $1.000B-$1.050B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":5101000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110174,"accession_number":"0000950103-26-000051","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb completes $2.8B term loan refinancing; margin cut up to 0.50%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Fourth Amendment providing $2,802,125,000 Replacement Term Loans maturing January 15, 2031.","Proceeds used to refinance existing term B loans due 2028 ($1.0B+) and 2031, extending maturity of 2028 tranche.","Applicable margin reduced by 0.50% (SOFR loans) to 3.75% and by 0.25% (base rate loans) to 2.75%.","Amortization set at 1.00% per annum with first installment due June 30, 2026.","Refinancing closed on January 2, 2026, as previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126732,"accession_number":"0001860742-25-000035","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb assigns new directors Alfonso, Collis to board committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eduardo C. Alfonso, MD appointed to Science and Technology Committee, effective Jan 1, 2026.","Steven H. Collis appointed to Talent and Compensation Committee, effective Jan 1, 2026.","Both were appointed to the Board effective same date as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126736,"accession_number":"0001193125-25-322866","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bausch + Lomb appoints Eduardo Alfonso, MD and Steven Collis to board, effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eduardo C. Alfonso, MD, and Steven H. Collis appointed to Bausch + Lomb board, effective Jan 1, 2026.","Appointments fill vacancies left by Brett Icahn and Gary Hu who departed in August 2025; board will have 10 directors.","Both new directors are independent under NYSE and TSX rules; no committee assignments announced.","Alfonso is a prominent ophthalmologist; Collis is former CEO of AmerisourceBergen (Fortune 10)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126735,"accession_number":"0000950103-25-016088","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb refinances $2.8B in term loans, cuts margins and extends maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Replacement Term Loans of $2,802M allocated to refinance all outstanding term B loans due 2028 and 2031.","Margin reduced by 0.50% on the existing 2031 term loans and 0.25% on the 2028 term loans; new margins at SOFR+3.75% or ABR+2.75%.","Maturity of the 2028 loans extended from Sept 29, 2028 to Jan 15, 2031, matching the existing 2031 maturity.","Transaction anticipated to close in Q1 2026, subject to customary conditions.","Net interest expense expected to decrease due to lower applicable margins on the refinanced debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126734,"accession_number":"0000950103-25-014656","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bausch + Lomb targets 5-7% revenue CAGR, ~23% EBITDA margin; pipeline peak sales ~$7B","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Targets 5-7% constant currency revenue CAGR 2025-2028.","Adjusted EBITDA margin (excl. Acq. IPR&D) target of ~23% in 2028.","Double-digit adjusted EPS growth (excl. Acq. IPR&D) expected 2026-2028.","Pipeline products projected peak sales of ~$7 billion; key launches include ELIOS MIGS (US 2H 2026) and PreserVision AREDS3 (1H 2026).","Net leverage target of ~3.5x by end of 2028; 2025 guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126733,"accession_number":"0001860742-25-000021","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q3 revenue $1.28B (+7% YoY); narrows FY adjusted EBITDA guidance to $870M-$910M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.281B, up 7% reported (6% constant currency); Vision Care +8%, Surgical +4%, Pharmaceuticals +8%.","GAAP net loss $28M ($0.08 loss per share) vs net income $4M ($0.01 EPS) in Q3 2024.","Adjusted EBITDA excluding acquired IPR&D $243M, up from $227M; adjusted EPS excl. IPR&D $0.18 vs $0.17.","FY 2025 revenue guidance reaffirmed at $5.05B-$5.15B; adjusted EBITDA guidance low end raised $10M to $870M-$910M.","Cash from operations $137M vs $154M; CEO cites pipeline and investor day as upcoming catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3696000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143523,"accession_number":"0001860742-25-000019","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.02","5.02","7.01","9.01"],"status":"ready","headline":"Bausch+Lomb's Icahn directors resign after agreement terminates","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Icahn and Gary Hu resigned from BLCO board effective August 14, 2025.","Resignations triggered by Icahn group's net long position in Bausch Health falling below threshold in the 2022 Director Appointment Agreement.","The Amended and Restated Director Appointment and Nomination Agreement terminated automatically on that date.","Resignations not due to any disagreement with Bausch+Lomb, per filing.","Chairman and CEO Brent Saunders thanked the departing directors for their service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143522,"accession_number":"0001860742-25-000016","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q2 revenue $1.278B, GAAP loss narrows to $62M, raises FY2025 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.278B, +5% as reported (+3% constant currency); Vision Care +8%, Surgical +3%, Pharma flat.","GAAP net loss $62M ($0.18 loss per share) vs $151M loss ($0.43) a year ago; adjusted net income $25M ($0.07 adjusted EPS).","Adjusted EBITDA $191M vs $209M prior year; Adj EBITDA ex-IPR&D $192M vs $212M.","Raised FY2025 guidance: revenue $5.05B-$5.15B (prior $5.0B-$5.1B), constant currency growth ~5-7%; Adj EBITDA ex-IPR&D $860M-$910M.","Resumed full production of enVista IOLs following recall; dry eye portfolio reached ~$1B trailing revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2415000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143521,"accession_number":"0000950103-25-009183","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb CEO amends employment agreement; PSUs now tied to share price and EBITDA goals through 2029","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brenton Saunders gave up 'good reason' severance right tied to spin-off timing from Bausch Health.","Amended PSUs vest Feb 23, 2029; payout range 120%-330% of target based on share-price hurdles ($26.57-$39.06).","Cumulative Adjusted EBITDA performance modifier for FY2025-2028 can adjust payout by -40% to +40%.","PSU payout also subject to Saunders' continued employment through the performance period.","Full text of amendments will be filed in Q3 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161710,"accession_number":"0001193125-25-149726","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb closes €675M notes offering and $2.325B term loan refinancing, extends maturities to 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€675M senior secured floating rate notes due Jan 15, 2031, at EURIBOR + 3.875%, priced at 99.5%.","$2.325B term B loans due 2031 at SOFR+4.25% or base+3.25%; $800M revolver replaced $500M revolver.","Proceeds used to repay 2027 term A and B loans and revolver; first-lien net leverage covenant raised to 5.75:1 (stepping down).","Term loans amortize at 1% per annum; first payment Sept 30, 2025.","Notes secured on first-priority basis by collateral also securing existing credit and senior secured notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161709,"accession_number":"0000950103-25-007603","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb prices €675M senior secured notes, upsizes term loan to $2.325B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuers priced €675M senior secured floating rate notes due 2031 at 99.500% of principal, upsized from €600M.","New $2.325B term B loan facility (Term SOFR + 4.25%) upsized from $2.2B; $800M revolver also planned.","Proceeds will repay existing revolver, refinance term A and B loans due 2027, and pay fees.","Notes offering and new credit facilities expected to close on June 26, 2025, subject to conditions.","Notes are guaranteed by Bausch + Lomb and secured by same assets as existing senior secured notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161708,"accession_number":"0000950103-25-007189","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb launches €600M notes offering and $2.2B term loan refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Subsidiaries launch €600M senior secured floating rate notes offering.","New $2.2B term B loan facility and $800M revolving credit facility planned.","Proceeds to repay existing revolver and refinance term A and B loans due 2027.","Notes offering not contingent on new credit facilities; secured by same collateral.","Transactions subject to market conditions; no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161707,"accession_number":"0001193125-25-124034","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bausch + Lomb shareholders elect all 10 director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with >99% support; broker non-votes ~8.4M.","Say-on-pay advisory vote approved: 326.9M for, 11.6M against, 1M abstain.","PricewaterhouseCoopers LLP ratified as independent auditor with 346.4M for, 1.5M withheld.","Meeting held May 21, 2025; all proposals carried as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161706,"accession_number":"0000950103-25-006266","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"B+L reports majority shareholder BHC enters standstill pacts with Icahn, Paulson, Kavanagh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Icahn, Paulson, and Kavanagh groups agree to resign from BHC/B+L boards if they engage in Specified Actions like proxy contests or buying >19.99% of BHC.","Icahn Group waives rights under the 2022 B+L DANA, including the right to designate a replacement director.","BHC commits to vote its B+L shares for management nominees from these groups as long as no Specified Action occurs.","B+L is not a party to the Letter Agreements; full terms are in BHC's Form 8-K filed May 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161705,"accession_number":"0001860742-25-000007","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 net loss $212M; enVista recall cuts FY adj. EBITDA guidance by ~$65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.137B (+3% reported, +5% constant currency) vs $1.099B YoY.","GAAP net loss $212M ($0.60/share); adjusted net loss $54M ($0.15/share).","Adjusted EBITDA excl. acquired IPR&D $126M, down from $180M YoY.","enVista IOL voluntary recall impacts: ~$55M revenue, ~$65M adj. EBITDA hit in FY 2025.","FY 2025 guidance: revenue $5.0B-$5.1B (previously $4.95B-$5.05B); adj. EBITDA $850M-$900M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1137000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179809,"accession_number":"0001860742-25-000003","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4 revenue up 11% CC; FY GAAP loss widens; guides 2025 revenue ~$5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.28B, up 9% reported and 11% constant currency, with growth across all segments.","FY GAAP net loss attributable $317M vs $260M loss in 2023; adjusted net income $204M vs $258M.","Adjusted EBITDA ex Acquired IPR&D FY $878M (+$140M); Q4 $259M (+$28M).","2025 guidance: revenue $4.95B-$5.05B (~5.5%-7.5% CC growth); Adj. EBITDA $900M-$950M; FX headwinds ~$100M revenue.","Dry eye portfolio approaching $1B annual revenue; contact lens double-digit Q4 growth; XIIDRA/MIEBO driving pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":4791000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196570,"accession_number":"0000950103-24-015809","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bausch + Lomb borrows $400M in incremental term loans; matures 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $400M in Second Incremental Term Loans under credit agreement dated May 10, 2022.","Term loans mature May 10, 2027; amortize quarterly starting Q1 2025.","Interest rate: base rate + 2.25% or term SOFR + 3.25%, at borrower's option.","Proceeds used to repay revolving credit facility and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196569,"accession_number":"0001860742-24-000016","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).","Adjusted EBITDA $212M ($227M ex-IPR&D) vs $187M YoY, driven by broad-based sales growth.","Pharmaceuticals revenue surged 76% to $306M on XIIDRA acquisition and MIEBO launch.","FY2024 revenue guidance raised to $4.725-4.825B (prior $4.70-4.80B); adjusted EBITDA outlook unchanged.","Cash flow from operations $154M, up from $48M YoY, aided by gross profit and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":3511000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212875,"accession_number":"0001860742-24-000011","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q2 revenue $1.216B (+17% YoY); GAAP net loss $151M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.216B, up 17% reported and 20% constant currency vs Q2 2023.","GAAP net loss attributable to BLCO $151M; adjusted EPS $0.13 (vs $0.18 a year ago).","Pharmaceuticals segment revenue surged 60% YoY to $310M, driven by XIIDRA acquisition and MIEBO launch.","Raised FY2024 revenue guidance to $4.7-4.8B (prev $4.6-4.7B) and adjusted EBITDA to $850-900M.","Adjusted EBITDA (non-GAAP) $209M, up from $179M in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2315000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231934,"accession_number":"0001193125-24-149259","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Shareholders approve 14M share increase to omnibus plan, elect all director nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2022 Omnibus Incentive Plan, adding 14M authorized common shares.","All 10 director nominees elected with >99% votes cast in favor; no contested seats.","Advisory vote on executive compensation passed with 328.7M for vs 15.9M against (95.4% support).","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year.","Approximately 347.6M shares voted on auditor ratification; absent broker non-votes on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231933,"accession_number":"0001860742-24-000007","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 revenue $1.099B (+18% YoY); raises FY constant-currency growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss attributable widened to $167M from $90M; adjusted EBITDA rose to $180M from $141M.","Vision Care revenue $635M (+8% reported, +11% constant currency); Surgical $197M (+8%); Pharmaceuticals $267M (+66% on XIIDRA/MIEBO).","Raises FY constant-currency revenue growth guidance to 13-15% from 12-14%; revenue range now $4.600-$4.700B.","Adjusted EPS (non-GAAP) $0.07 vs $0.10; GAAP EPS ($0.48) vs ($0.26).","Cash from operations $41M vs use of $56M in Q1 2023; foreign-exchange headwind estimated at $90M for FY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":1099000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250224,"accession_number":"0001193125-24-049266","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch + Lomb appoints Karen Ling to board; Richard De Schutter to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard De Schutter will not stand for re-election at the 2024 annual meeting; retirement not due to any disagreement.","Karen Ling appointed as director effective February 27, 2024, temporarily expanding board to 11 members.","Ling is former EVP and CHRO at AIG and Allergan; previously held senior HR roles at Merck and Wyeth.","Board expected to revert to 10 members after De Schutter's retirement at the 2024 annual meeting.","Ling is independent per NYSE and TSX rules; committee assignments not yet determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250223,"accession_number":"0001860742-24-000003","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4 rev $1.17B (+18% YoY); guides FY 2024 rev $4.6-4.7B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $1.173B (+18% YoY); full-year revenue $4.146B (+10% YoY).","GAAP net loss attributable to BLCO: Q4 $54M, FY $260M; prior year Q4 loss $1M, FY income $6M.","Adjusted EBITDA Q4 $231M (+$50M YoY); FY $738M (+$18M YoY). 2024 guidance: $840-$890M.","Pharmaceuticals segment revenue up 67% in Q4 driven by XIIDRA acquisition and MIEBO launch.","Cash flow from operations negative $17M for FY 2023 vs +$345M in 2022 due to inventory build and timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":4146000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267767,"accession_number":"0001193125-23-276133","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2023-11-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Bausch+Lomb completes $1.75B XIIDRA acquisition; issues $1.9B in debt at 8.375%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Sep 29, 2023; upfront cash $1.75B, potential milestones up to $750M.","Financed with $1.9B debt: $1.4B 8.375% Senior Secured Notes due Oct 2028 and $500M term B loans.","Pro forma long-term debt rises to $4.464B (from $2.604B); total assets $13.185B.","Acquired Assets add $1.72B in intangible assets; goodwill increases by $23M.","Pro forma financials reflect transaction accounting adjustments; no integration synergies assumed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267766,"accession_number":"0001860742-23-000032","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2023-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb discloses separation agreement terms for departing President Joseph Gordon","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cash severance of $2,203,200 (2x base salary plus target bonus).","Prorated 2023 annual bonus based on actual performance, paid by March 15, 2024.","Health coverage through second anniversary of Nov 30, 2023 separation date.","Unpaid spinoff bonus of $250,000 and legal fee reimbursement up to $5,000.","Time-based RSUs and stock options from March 1, 2023 continue vesting through March 1, 2024 consulting period; non-solicit extended to 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267768,"accession_number":"0001860742-23-000026","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q3 revenue $1.007B, raises full-year 2023 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.007B (+7% YoY, +8% constant currency); GAAP net loss of $84M vs $18M loss prior year.","Adjusted EBITDA $187M (flat YoY); adjusted EPS $0.22 (vs $0.31 prior year).","Full-year 2023 revenue guidance raised to $4.035-$4.085B; Adjusted EBITDA guidance raised to $710-$760M.","Vision Care revenue rose 9% to $648M; Surgical up 8% to $185M; Pharmaceuticals flat at $174M.","Launched MIEBO for dry eye and acquired XIIDRA; distribution system upgrade impacted contact lens sales, expected to resolve in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2973000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284997,"accession_number":"0001193125-23-247434","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","2.01","9.01","2.03"],"status":"ready","headline":"Bausch + Lomb completes $2.5B acquisition of XIIDRA from Novartis, funded by $1.4B notes and $500M term loans","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired XIIDRA, libvatrep (Phase 2b), and AcuStream tech from Novartis for up to $2.5B ($1.75B upfront + $750M milestones).","Funded with $1.4B of 8.375% senior secured notes due 2028 and $500M incremental term B loans.","XIIDRA adds non-steroid dry eye treatment; combined with MIEBO, targets leading position in growing prescription DED market.","Libvatrep Phase 2b study results expected H2 2023; AcuStream device aims at precise ophthalmic dosing.","CEO Brent Saunders expects to 'quickly take a leading position in the growing prescription dry eye category.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284996,"accession_number":"0001193125-23-235410","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb prices $1.4B 8.375% senior secured notes due 2028 for XIIDRA acquisition financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $1.4B aggregate principal of 8.375% senior secured notes due 2028 at par; closing expected Sept 29, 2023.","Also plans $500M incremental term B loans under existing credit facility; drawn upon acquisition close.","Net proceeds to fund pending acquisition of XIIDRA (lifitegrast ophthalmic solution) and other ophthalmology assets.","If notes issued before acquisition close, proceeds held in escrow by Bausch + Lomb Escrow Corp.; B+L assumes after close.","If acquisition not closed by Sept 30, 2024, Escrow Issuer must redeem notes at principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284995,"accession_number":"0001193125-23-231974","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Bausch + Lomb launches $1.4B notes offering and $500M term loans to finance XIIDRA acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$1.4B senior secured notes due 2028 offered via Bausch + Lomb Escrow Corp.; $500M term B loans also planned.","Proceeds to fund acquisition of XIIDRA and other ophthalmology assets, pay fees, and repay existing debt.","Notes offering not conditioned on acquisition close; if not closed by Sept 30, 2024, notes redeemed at principal plus interest.","Purchase price allocation adjusted: prepaid assets reduced $22M, other liabilities cut $12M, goodwill up $10M; no impact on revenue or adjusted EBITDA.","Acquisition expected to close around end of September 2023; term loan facility conditioned on completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284994,"accession_number":"0001193125-23-229767","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bausch + Lomb provides financials for Novartis XIIDRA acquisition; $1.75B upfront plus $750M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of XIIDRA (lifitegrast) and certain ophthalmology assets from Novartis for $1.75B upfront and up to $750M milestone payments.","Closing expected at or around end of September 2023, subject to customary conditions.","Acquired assets had net revenue of $487M in 2022 and $468M in 2021, with total comprehensive shortfall of $384M in 2022.","Net assets acquired were $2.065B as of Dec 31, 2022, including $2.138B intangible asset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284991,"accession_number":"0001860742-23-000023","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2023-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb discloses separation terms for former EVP & General Counsel Ackermann","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cash severance of $2,754,000 (2x base salary and target bonus) for Christina Ackermann.","Additional $280,000 lump sum and proration of founder equity awards; non-solicit extended to 24 months.","Prorated 2023 bonus based on actual performance; health coverage through second anniversary of separation.","$250,000 spinoff bonus unpaid portion and $20,000 outplacement services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284993,"accession_number":"0001860742-23-000018","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb reports Q2 2023 results; no specific figures provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed under Item 2.02; press release issued on August 2, 2023.","Exhibit 99.1 referenced but not included in the submitted text.","No financial metrics (revenue, EPS, segment data) available for analysis.","Company trades on NYSE and TSX under ticker BLCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1966000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284992,"accession_number":"0001193125-23-183284","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bausch + Lomb to acquire Xiidra and other ophthalmology assets from Novartis for $1.75B cash plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $1.75B in cash at closing, plus up to $750M in milestone payments tied to sales and pipeline achievements.","Transaction expected to close by end of fiscal year 2023, subject to HSR and other customary closing conditions.","Bausch + Lomb subsidiary will make offers of employment to certain Novartis employees of the acquired business.","Buyer has obtained debt financing commitments and Parent (Bausch + Lomb) has guaranteed Buyer's obligations.","Termination fee of $100M payable by Buyer if certain breaches occur or if transaction fails to close under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304812,"accession_number":"0001193125-23-179447","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb agrees to acquire XIIDRA from Novartis for up to $2.5B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $1.75B plus up to $750M in milestones; total consideration up to $2.5B.","XIIDRA generated ~$487M in sales in 2022; patented through 2033.","Acquisition includes libvatrep (Phase 2b) and AcuStream device.","Expected close by end of 2023; immediately accretive; J.P. Morgan committed financing.","B+L expects to return to current leverage within ~24 months post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304811,"accession_number":"0000950103-23-008261","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bausch + Lomb reshapes exec team; Gordon becomes advisor, business unit heads elevated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph F. Gordon transitions from President, Global Consumer, Surgical and Vision Care to strategic advisor to CEO Brent Saunders, effective June 1, 2023.","Three business unit heads — Luc Bonnefoy (Surgical), John Ferris (Consumer), Yang Yang (Vision Care) — join executive management team, reporting directly to CEO.","EVP and Chief Quality Officer Louis Yu plans to retire later this summer; Company will conduct internal and external search for replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304810,"accession_number":"0001860742-23-000012","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb reports Q1 2023 results; specific figures not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Issued press release on May 3, 2023 covering Q1 2023 financial results.","Exhibit 99.1 with detailed financials was attached to the filing but not included in the provided text.","No revenue, EPS, or segment data can be extracted from the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":931000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304809,"accession_number":"0001193125-23-117046","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Bausch + Lomb shareholders approve 10M share increase for incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2022 Omnibus Incentive Plan, adding 10,000,000 common shares for issuance.","All 10 director nominees elected with strong support; highest against vote was 4,014,230 for Thomas W. Ross, Sr.","Advisory vote on executive compensation passed with 338,615,408 for vs 5,599,325 against.","Shareholders selected annual frequency for future say-on-pay votes (341,717,168 for 1 year).","PricewaterhouseCoopers LLP reappointed as independent auditor with 346,413,418 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304808,"accession_number":"0000950103-23-005621","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bausch + Lomb appoints new Chief Legal Officer and Ophthalmic Pharma President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christina Ackermann steps down as EVP & General Counsel and President, Ophthalmic Pharmaceuticals; departure effective April 28, 2023.","Bob Bailey appointed EVP & Chief Legal Officer, effective April 24, 2023.","Andrew Stewart appointed President, Ophthalmic Pharmaceuticals, effective April 24, 2023.","Bailey previously served as CLO at Datavant and Allergan; Stewart joins from AbbVie eye care.","Both Bailey and Stewart will join the executive management team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324343,"accession_number":"0001860742-23-000004","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4/FY2022 earnings: no specific figures in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on Feb 22, 2023, for Q4 and full year ended Dec 31, 2022.","No specific financial figures available in the provided filing excerpt.","Investors should refer to the full press release for details."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":3768000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324342,"accession_number":"0001193125-23-039729","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch + Lomb appoints Brent Saunders as CEO and Chair, effective March 6, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brent Saunders appointed CEO and Chair, effective March 6, 2023; Joseph Papa steps down.","Saunders previously served as CEO of Bausch + Lomb from 2010-2013; over 25 years healthcare leadership.","Employment agreement: $1.6M base salary, $6.5M cash sign-on bonus, equity grants of 750k PSUs, 1.32M options, 375k RSUs.","Saunders will join Feb 16 in advisory capacity; Thomas Ross becomes Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342253,"accession_number":"0001860742-22-000030","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch + Lomb CEO Joseph Papa to remain until March–June 2023; severance amended","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Joseph C. Papa to serve through at least March 4, 2023, and no later than June 30, 2023, under amended separation agreement.","Board continues search for a new CEO; Papa’s departure date tied to successor appointment or Board discretion.","Papa receives $1.2M prorated target bonus (50% of target) on termination, replacing performance-based bonus.","Accelerated vesting of 315,592 RSUs (shares remain restricted until distribution, change of control, or 2-year anniversary) and 1,248,496 stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342252,"accession_number":"0001860742-22-000023","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q3 2022 earnings press release issued; no figures available from this filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["The 8-K states a press release was issued on November 2, 2022, for Q3 2022 results.","The press release (Exhibit 99.1) was not included in the provided text.","Without the exhibit, specific financial performance cannot be summarized.","Ticker: BLCO (NYSE and TSX)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":2772000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359021,"accession_number":"0001860742-22-000016","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb reports Q2 2022 results; press release exhibit not provided for analysis","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on August 4, 2022, announcing Q2 2022 results.","Press release attached as Exhibit 99.1 but full text is unavailable in the filing text.","No specific revenue, EPS, segment data, or guidance figures can be extracted.","Investors should refer to the full press release for complete financial details."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1830000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359020,"accession_number":"0000950103-22-013065","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb CEO Joseph C. Papa departing; retention program approved for other NEOs","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["CEO Joseph C. Papa to leave; successor search ongoing.","Talent committee approved enhanced severance for other NEOs (2x salary + target bonus) for qualifying termination within one year after successor appointed.","Founder Awards granted in May 2022 get pro-rata vesting but shares/options remain restricted until spin-off, change of control, strategy change, or 2-year anniversary.","Each eligible NEO granted 35,000 RSUs under retention program, vesting 1/3 per year over 3 years.","Retention program aims to stabilize leadership during CEO transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-27T23:59:59+00:00|359020"}